Use of KRAS mutation status to predict clinical outcomes in patients with metastatic colorectal cancer (mCRC) treated with the VEGF signaling inhibitor cediranib.J.M. Jürgensmeier, Jeff Smith, Laura A. Pike et al.|Journal of Clinical Oncology|2011Cited by 3